Deutsch English Français

Contact

EP2456428

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2456428

EP2456428 - SELECTIVE CB2 RECEPTOR AGONISTS FOR USE IN THE PREVENTION OR TREATMENT OF ALCOHOLIC LIVER DISEASE [Right-click to bookmark this link]
Status	The application has been refused Status updated on 18.03.2016 Database last updated on 19.10.2024
Most recent event Tooltip	18.03.2016	Refusal of application	published on 20.04.2016 [2016/16]
Applicant(s)	For all designated states INSERM - Institut National de la Santé et de la Recherche Médicale 101, rue de Tolbiac 75013 Paris / FR
	[2012/22]
Inventor(s)	01 / LOTERSZTAJN, Sophie Inserm U995 - équipe 17 Hopital Henri Mondor 51 Avenue du Maréchal de Lattre de Tassigny F-94010 Creteil / FR
	02 / TEIXEIRA-CLERC, Fatima Inserm U995 - équipe 17 Hopital Henri Mondor 51 Avenue du Maréchal de Lattre de Tassigny F-94010 Creteil / FR
	03 / MALLAT, Ariane Inserm U995 - équipe 17 Hopital Henri Mondor 51 Avenue du Maréchal de Lattre de Tassigny F-94010 Creteil / FR
	04 / LOUVET, Alexandre Service des malades de l'appareil digestif Hopital Huriez Rue Polonovski F-59037 Cedex Lille / FR
	[2012/22]
Representative(s)	Cabinet Nony 11 rue Saint-Georges 75009 Paris / FR
	[N/P]
Former [2014/21]	Nony 3, rue de Penthièvre 75008 Paris / FR
Former [2012/22]	Hirsch, Denise Marie Inserm-Transfert Industrial Property Department Biopark 7 rue Watt 75013 Paris / FR
Application number, filing date	10737313.6	21.07.2010
	WO2010EP60556
Priority number, date	EP20090305700	23.07.2009 Original published format: EP 09305700
	[2012/22]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2011009883
	Date:	27.01.2011
	Language:	EN
	[2011/04]
	Type:	A1 Application with search report
	No.:	EP2456428
	Date:	30.05.2012
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 27.01.2011 takes the place of the publication of the European patent application.
	[2012/22]
Search report(s)	International search report - published on:	EP	27.01.2011
Classification	IPC:	A61K31/00, A61K31/352, A61P1/16	[2012/22]
	CPC:	A61K31/352 (EP,US); A61P1/16 (EP)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR [2012/22]
Title	German:	SELEKTIVE CB2-REZEPTORAGONISTEN ZUR PRÄVENTION ODER BEHANDLUNG VON ALKOHOLBEDINGTEN LEBERERKRANKUNGEN	[2012/22]
	English:	SELECTIVE CB2 RECEPTOR AGONISTS FOR USE IN THE PREVENTION OR TREATMENT OF ALCOHOLIC LIVER DISEASE	[2012/22]
	French:	AGONISTES SÉLECTIFS DU RÉCEPTEUR CB2 DESTINÉS À ÊTRE UTILISÉS DANS LA PRÉVENTION OU LE TRAITEMENT D'UNE MALADIE HÉPATIQUE ALCOOLIQUE	[2012/22]
Entry into regional phase	25.01.2012	National basic fee paid
	25.01.2012	Designation fee(s) paid
	25.01.2012	Examination fee paid
Examination procedure	25.01.2012	Amendment by applicant (claims and/or description)
	25.01.2012	Examination requested [2012/22]
	12.05.2014	Despatch of a communication from the examining division (Time limit: M04)
	11.08.2014	Reply to a communication from the examining division
	24.11.2015	Date of oral proceedings
	03.12.2015	Despatch of communication that the application is refused, reason: substantive examination [2016/16]
	03.12.2015	Minutes of oral proceedings despatched
	13.12.2015	Application refused, date of legal effect [2016/16]
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 12.05.2014
Fees paid	Renewal fee
	23.07.2012	Renewal fee patent year 03
	24.07.2013	Renewal fee patent year 04
	23.07.2014	Renewal fee patent year 05
	24.07.2015	Renewal fee patent year 06
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[X]US7320805 (GRENARD PASCALE [FR], et al) [X] 1,3,4 * abstract * * column 9, line 62, paragraph B - column 11, line 21 * * column 9, lines 14-18,29-43 *;
		[X]WO2008050344 (YISSUM RES DEV CO [IL], et al) [X] 1,4 * abstract *;
		[A]US2008194674 (GRENARD PASCALE [FR], et al) [A] 1-5 * column 5, paragraph 40 - column 6, paragraph 55; claims 1,2,4,5 *;
		[A] - BELOT M P ET AL, "CANNABINOID CB2 RECEPTORS STIMULATE LIVER REGENERATION", JOURNAL OF HEPATOLOGY, vol. 50, ISSN 0168-8278, (20090401), pages S44 - ABS 108, (20090401), XP026495721 [A] 1-5 * abstract * DOI: http://dx.doi.org/10.1016/S0168-8278(09)60110-0
		[A] - DEVEAUX VANESSA ET AL, "Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, SAN FRANCISCO, CA, US, (20090101), vol. 4, no. 6, ISSN 1932-6203, pages e5844 - 1, XP009126298 [A] 1-5 * abstract *
		[A] - ASHTON J C, "Cannabinoids for the treatment of inflammation", CURRENT OPINION IN INVESTIGATIONAL DRUGS, (200705), vol. 8, no. 5, ISSN 1472-4472, pages 373 - 384, XP009126332 [A] 1-5 * abstract *
		[XP] - LOUVET A ET AL, "BENEFICIAL EFFECTS OF CANNABINOID RECEPTOR 2 ON ALCOHOLIC LIVER DISEASE", JOURNAL OF HEPATOLOGY, & 45TH ANNUAL MEETING OF THE EUROPEAN-ASSOCIATION-FOR-THE-STUDY-OF-THE- LIVER; VIENNA, AUSTRIA; APRIL 14 -18, 2010, vol. 52, no. Suppl. 1, ISSN 0168-8278, (20100401), pages S307 - S308, (20100401), XP026998690 [XP] 1-5 * abstract *
		[XP] - LOUVET ALEXANDRE ET AL, "CANNABINOID RECEPTOR 2 PROTECTS FROM ALCOHOLIC LIVER DISEASE", HEPATOLOGY, & 60TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-THE-STUDY-OF-LIVE R-DISEASES; BOSTON, MA, USA; OCTOBER 30 -NOVEMBER 03, 2009, (200910), vol. 50, no. 4, Suppl. S, ISSN 0270-9139, pages 325A - 326A, XP009137660 [XP] 1-5 * abstract *
	Examination	CN101306147
		JPH07223963
		- Ganesh A Thaku, "Latest advances in cannabinoid receptor agonists", Expert Opinion on Therapeutic patents, doi:10.1517/13543770903436505 , (20090101), pages 1647 - 1673, URL: http://informahealthcare.com/doi/pdf/10.1517/13543770903436505, (20120523), XP055027895 DOI: http://dx.doi.org/10.1517/13543770903436505©
	by applicant	US2005143448
		WO2006138656
		US2005165118
		US2004034090
		US7214716
		US6013648
		US5605906
		WO02085866
		WO0132169
		WO0128497
		WO9700860
		WO9618391
		US2004077643
		US2002173528
		EP1306373
		EP1374903
		US4946778
		US5225539
		US4816397
		US4683202
		US5854033
		- BARANY, PROC. NATL. ACAD. SCI. USA, (1991), vol. 88, pages 189 - 193
		- BUCKLEY NE; MCCOY KL; MEZEY E; BONNER T; ZIMMER A ET AL., "Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor", EUR J PHARMACOL, (2000), vol. 396, pages 141 - 149
		- DEVEAUX V; CADOUDAL T; ICHIGOTANI Y; TEIXEIRA-CLERC F; LOUVET A; MANIN S; NHIEU JT; BELOT MP; ZIMMER A; EVEN P, "Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis", PLOS ONE, (20090609), vol. 4, no. 6, page E5844
		- FACCI L; DAL TOSO R; ROMANELLO S; BURIANI A; SKAPER SD; LEON A, "Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide", PROC NATL ACAD SCI U S A., (19950411), vol. 92, no. 8, pages 3376 - 80
		- GUATELLI ET AL., PROC. NATL. ACAD. SCI. USA, (1990), vol. 57, pages 1874 - 1878
		- GUSTOT, T.; LEMMERS, A.; MORENO, C.; NAGY, N.; QUERTINMONT, E.; NICAISE, C.; FRANCHIMONT, D.; LOUIS, H.; DEVIERE, J.; LE MOINE, O., "Differential liver sensitization to toll-like receptor pathways in mice with alcoholic fatty liver", HEPATOLOGY, (2006), vol. 43, pages 989 - 1000
		- HANUS L; BREUER A; TCHILIBON S; SHILOAH S; GOLDENBERG D; HOROWITZ M; PERTWEE RG; ROSS RA; MECHOULAM R; FRIDE E, "HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor", PROC NATL ACAD SCI U S A., (19991207), vol. 96, no. 25, pages 14228 - 33
		- HUFFMAN JW; LIDDLE J; YU S; AUNG MM; ABOOD ME; WILEY JL; MARTIN BR, "3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor", BIOORG MED CHEM., (199912), vol. 7, no. 12, pages 2905 - 14
		- JULIEN B; GRENARD P; TEIXEIRA-CLERC F; VAN NHIEU JT; LI L; KARSAK M; ZIMMER A; MALLAT A; LOTERSZTAJN S, "Antifibrogenic role of the cannabinoid receptor CB2 in the liver", GASTROENTEROLOGY, (200503), vol. 128, no. 3, pages 742 - 55
		- KOHLER G; MILSTEIN C, "Continuous cultures of fused cells secreting antibody of predefined specificity", NATURE, (1975), vol. 256, no. 5517, pages 495 - 7
		- KWOH ET AL., PROC. NATL. ACAD. SCI. USA, (1989), vol. 86, pages 1173 - 1177
		- LIZARDI ET AL., BIOL. TECHNOLOGY, (1988), vol. 6, page 1197
		- MATSUDA ET AL., NATURE (LOND), (1990), vol. 346, pages 561 - 564
		- PARFIENIUK A; FLISIAK R, "Role of cannabinoids in chronic liver diseases", WORLD J GASTROENTEROL., (20081028), vol. 14, no. 40, pages 6109 - 14
		- PERTWEE RG, "Pharmacology of cannabinoid receptor ligands", CURR MED CHEM., (199908), vol. 6, no. 8, pages 635 - 64
		- RINALDI-CARMONA M; CALANDRA B; SHIRE D; BOUABOULA M; OUSTRIC D; BARTH F; CASELLAS P; FERRARA P; LE FUR G, "Characterization of two cloned human CB1 cannabinoid receptor isoforms", J PHARMACOL EXP THER., (199608), vol. 278, no. 2, pages 871 - 8
		- RINALDI-CARMONA ET AL., J. PHARMACOL. EXPT. THER., (1998), vol. 284, pages 644 - 650
		- TEIXEIRA-CLERC F; JULIEN B; GRENARD P; TRAN VAN NHIEU J; DEVEAUX V; LI L; SERRIERE-LANNEAU V; LEDENT C; MALLAT A; LOTERSZTAJN S, "CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis", NAT MED., (200606), vol. 12, no. 6, pages 671 - 6

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p